ID | 115074 |
Title Alternative | Prediction Models for BMI and NAFLD
|
Author |
Oniki, Kentaro
Kumamoto University
Watanabe, Takehisa
Kumamoto University
Kudo, Miku
Kumamoto University
Izuka, Tomoko
Kumamoto University
Ono, Tatsumasa
Kumamoto University
Matsuda, Kazuki
Kumamoto University
Sakamoto, Yuki
Kumamoto University
Nagaoka, Katsuya
Kumamoto University
Imafuku, Tadashi
Kumamoto University
Watanabe, Hiroshi
Kumamoto University
Maruyama, Toru
Kumamoto University
Otake, Koji
Japanese Red Cross Kumamoto Health Care Center
Ogata, Yasuhiro
Kumamoto University
Saruwatari, Junji
Kumamoto University
|
Content Type |
Journal Article
|
Description | Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity. Disulfide bond‐forming oxidoreductase A‐like protein (DsbA‐L) is known to be a key molecule in protection against obesity and obesity‐induced inflammation. In the present study, we used a modeling and simulation approach in an attempt to develop body mass index (BMI) and BMI‐based NAFLD prediction models incorporating the DsbA‐L polymorphism to predict the BMI and NAFLD in 341 elderly subjects. A nonlinear mixed‐effect model best represented the sigmoidal relationship between the BMI and the logit function of the probability of NAFLD prevalence. The final models for BMI and NAFLD showed that DsbA‐L rs1917760 polymorphism, age, and gender were associated with the BMI, whereas gender, patatin‐like phospholipase 3 rs738409 polymorphism, HbA1c, and high‐density and low‐density lipoprotein cholesterol levels were associated with the risk of NAFLD. This information may aid in the genetic‐based prevention of obesity and NAFLD in the general elderly population.
|
Journal Title |
CPT: Pharmacometrics & Systems Pharmacology
|
ISSN | 21638306
|
Publisher | American Society for Clinical Pharmacology and Therapeutics|Wiley
|
Volume | 7
|
Issue | 6
|
Start Page | 384
|
End Page | 393
|
Published Date | 2018-03-23
|
Rights | © 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Pharmaceutical Sciences
|